FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945973359> ?p ?o ?g. }

• W2945973359 endingPage "65" @default.
• W2945973359 startingPage "54" @default.
• W2945973359 abstract "Summary Background Tioguanine (or thioguanine) is an alternative drug for IBD patients who fail prior conventional immunomodulating therapy. Aim To report effectiveness, safety and therapeutic drug monitoring in a cohort of patients with prolonged tioguanine maintenance therapy. Methods In this nationwide, multicentre study, medical records of tioguanine‐ using IBD patients were retrospectively reviewed. Response to therapy was defined as clinical effectiveness without (re)initiation of corticosteroids, concurrent biological therapy or surgical intervention. All adverse events that occurred during the follow‐up were listed and graded according to the common terminology criteria (CTC). Results Two hundred and seventy‐four patients (female 63%, Crohn's disease in 68%) were included with median treatment duration of 51 months, 1567 patient‐years of follow‐up and median 20 mg/d tioguanine dosage. Tioguanine was tolerated in 79%, clinical effectiveness at 6 months was documented in 66% and sustained clinical effectiveness during 12 months in 51% of patients. Forty‐one per cent of patients developed adverse events: 5% were graded as severe. Adverse events comprised infection requiring hospitalisation in three and skin cancer in eight patients (two melanomas). Asymptomatic nodular regenerative hyperplasia of the liver occurred in two out of 52 patients with liver biopsies (3.8%) and portal hypertension in three whereof one potentially associated with tioguanine (0.4%). Clinical effectiveness was correlated with 6‐thioguanine nucleotide threshold concentrations >682 pmol/8×10 8 RBC ( P < 0.05). Conclusions Long‐term tioguanine therapy for at least 12 months was effective in 51% and well tolerated as a maintenance treatment for IBD in about 70% of patients. Adverse events were common, but mainly mild or moderate. 6‐Thioguanine nucleotide threshold concentration ≥ 700 pmol/8×10 8 RBC is proposed as target level with higher odds for clinical effectiveness." @default.
• W2945973359 created "2019-05-29" @default.
• W2945973359 creator A5000077620 @default.
• W2945973359 creator A5005045924 @default.
• W2945973359 creator A5005755289 @default.
• W2945973359 creator A5010186562 @default.
• W2945973359 creator A5030473387 @default.
• W2945973359 creator A5039341334 @default.
• W2945973359 creator A5042969825 @default.
• W2945973359 creator A5055821849 @default.
• W2945973359 creator A5065293355 @default.
• W2945973359 creator A5067248190 @default.
• W2945973359 creator A5069308614 @default.
• W2945973359 creator A5072029105 @default.
• W2945973359 date "2019-05-16" @default.
• W2945973359 modified "2023-10-16" @default.
• W2945973359 title "Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies" @default.
• W2945973359 cites W1963889098 @default.
• W2945973359 cites W1968248147 @default.
• W2945973359 cites W1968626722 @default.
• W2945973359 cites W1972388266 @default.
• W2945973359 cites W1981097265 @default.
• W2945973359 cites W1985141290 @default.
• W2945973359 cites W2012893442 @default.
• W2945973359 cites W2022787044 @default.
• W2945973359 cites W2026679422 @default.
• W2945973359 cites W2027775465 @default.
• W2945973359 cites W2028547310 @default.
• W2945973359 cites W2030471467 @default.
• W2945973359 cites W2040402881 @default.
• W2945973359 cites W2061446694 @default.
• W2945973359 cites W2065637841 @default.
• W2945973359 cites W2071198368 @default.
• W2945973359 cites W2083576502 @default.
• W2945973359 cites W2091346856 @default.
• W2945973359 cites W2102013054 @default.
• W2945973359 cites W2108236283 @default.
• W2945973359 cites W2131632358 @default.
• W2945973359 cites W2135400982 @default.
• W2945973359 cites W2139547491 @default.
• W2945973359 cites W2157692976 @default.
• W2945973359 cites W2158585848 @default.
• W2945973359 cites W2163571143 @default.
• W2945973359 cites W2486530646 @default.
• W2945973359 cites W2516473081 @default.
• W2945973359 cites W2546364259 @default.
• W2945973359 cites W2583464358 @default.
• W2945973359 cites W2587735546 @default.
• W2945973359 cites W2752901244 @default.
• W2945973359 cites W2758842029 @default.
• W2945973359 cites W2767910653 @default.
• W2945973359 cites W2781372331 @default.
• W2945973359 cites W2792047376 @default.
• W2945973359 cites W2793225128 @default.
• W2945973359 cites W2806337540 @default.
• W2945973359 cites W2885796666 @default.
• W2945973359 cites W2900687531 @default.
• W2945973359 doi "https://doi.org/10.1111/apt.15280" @default.
• W2945973359 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6618772" @default.
• W2945973359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31094013" @default.
• W2945973359 hasPublicationYear "2019" @default.
• W2945973359 type Work @default.
• W2945973359 sameAs 2945973359 @default.
• W2945973359 citedByCount "26" @default.
• W2945973359 countsByYear W29459733592019 @default.
• W2945973359 countsByYear W29459733592020 @default.
• W2945973359 countsByYear W29459733592021 @default.
• W2945973359 countsByYear W29459733592022 @default.
• W2945973359 countsByYear W29459733592023 @default.
• W2945973359 crossrefType "journal-article" @default.
• W2945973359 hasAuthorship W2945973359A5000077620 @default.
• W2945973359 hasAuthorship W2945973359A5005045924 @default.
• W2945973359 hasAuthorship W2945973359A5005755289 @default.
• W2945973359 hasAuthorship W2945973359A5010186562 @default.
• W2945973359 hasAuthorship W2945973359A5030473387 @default.
• W2945973359 hasAuthorship W2945973359A5039341334 @default.
• W2945973359 hasAuthorship W2945973359A5042969825 @default.
• W2945973359 hasAuthorship W2945973359A5055821849 @default.
• W2945973359 hasAuthorship W2945973359A5065293355 @default.
• W2945973359 hasAuthorship W2945973359A5067248190 @default.
• W2945973359 hasAuthorship W2945973359A5069308614 @default.
• W2945973359 hasAuthorship W2945973359A5072029105 @default.
• W2945973359 hasBestOaLocation W29459733591 @default.
• W2945973359 hasConcept C126322002 @default.
• W2945973359 hasConcept C141071460 @default.
• W2945973359 hasConcept C167135981 @default.
• W2945973359 hasConcept C195910791 @default.
• W2945973359 hasConcept C197934379 @default.
• W2945973359 hasConcept C2777793932 @default.
• W2945973359 hasConcept C2777910003 @default.
• W2945973359 hasConcept C71924100 @default.
• W2945973359 hasConcept C72563966 @default.
• W2945973359 hasConceptScore W2945973359C126322002 @default.
• W2945973359 hasConceptScore W2945973359C141071460 @default.
• W2945973359 hasConceptScore W2945973359C167135981 @default.
• W2945973359 hasConceptScore W2945973359C195910791 @default.
• W2945973359 hasConceptScore W2945973359C197934379 @default.
• W2945973359 hasConceptScore W2945973359C2777793932 @default.

• next